|
|
| Drug Name: | Lidocaine Hydrochloride |
| Manufacturer: | INTERNATIONAL MEDICATION SYSTEMS, LIMITED |
| Other Info: | Rx OnlyManufactured under U.S. Pat. No. 3,941,131.INTERNATIONAL MEDICATION SYSTEMS, LIMITEDSOUTH EL MONTE, CA 91733, U.S.A.An Amphastar Pharmaceuticals CompanyREV. 8-046930120L |
| Clinical Trials: | |
EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS.
PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT.THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.Lidocaine Hydrochloride Jelly USP, 2% should be used with extreme caution in the presence of sepsis or severely traumatized mucosa in the area of application, since under such conditions there is the potential for rapid systemic absorption.When used for endotracheal tube lubrication, care should be taken to avoid introducing the product into the lumen of the tube.
Do not use the jelly to lubricate the endotracheal stylettes.
lf allowed into the inner lumen, the jelly may dry on the inner surface leaving a residue which tends to clump with flexion, narrowing the lumen.
There have been rare reports in which this residue has caused the lumen to occlude.
See also ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION.
NIH - Clinical Trials